Fundraising FoxVertex Ventures HC — Full Portfolio
14 tracked investments · listed companies and verified rows first
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge, GB
Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalDementia Discovery FundLongwood FundRidgeback Capital+4 more
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestRA CapitalWellington ManagementAlexandriaCity Hill Ventures+3 more
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases.
BiotechHealthtechHouston, US
Guy DiPierro(Chief Operating Officer & Co-Founder)inSungjin Kim(Scientific Founder)John Sunwoo(Scientific Founder)Mark W. Frohlich(Chief Executive Officer)Stefanie Mandl-Cashman(Acting Chief Scientific Officer)
Co-investorsLeaps by BayerRA Capital
Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.
BiotechMedical DevicesSan Diego, US
Pam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Co-founder and first Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)Pam Taub, M.D., FACC(Co-founder)
Co-investorsBluebird VenturesBroadview VenturesLongitude CapitalAdams Street PartnersARCH Venture PartnersVertex Ventures
HealthtechFremont, US
Anton Clifford(Executive Officer)inJames Leech(Executive Officer)inChristopher Gleason(Executive Officer)inKevin K. Sidow(Executive Officer, Director)
BoardJoshua Makower(Director)Shahzad Malik(Director)in
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Runway Growth CapitalAdvent Life SciencesGBS Venture Partners Ltd.Gilde Healthcare+1 more
Neuspera Medical develops an integrated sacral neuromodulation (iSNM) system that implants a smart neurostimulator near the sacral nerve to treat urinary urge incontinence, a symptom of overactive bladder.
BiotechHealthtechMedical DevicesSan Jose, US
Alexander Yeh(Founder)inMilton M. Morris(Executive Officer, Director)inDave Van Meter(Chief Executive Officer)Steve Paul(Chief Commercial Officer)in
Co-investorsAlumni VenturesCerity Partners VenturesForeground CapitalPortfoliaTreo Ventures, LlcWindham Capital Partners+2 more
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.
BiotechHealthtech
Peter Barrett(Co-founder & Board Member)inTom Wandless(Scientific Founder)Madan Jagasia(Chief Executive Officer)inParameswaran Hari(Chief Medical Officer)inJulie Feder(Chief Financial Officer)inDana Alexander(Chief Technical Officer)in
Co-investorsAtlas VentureTCG CrossoverWellington Management
Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.
BiotechDigital HealthMedical DevicesWaltham, US
Jim Broderick(Co-Founder)inJohn Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)Li Peng(Chief Scientific Officer)
Co-investorsMatrix Capital ManagementPfizer VenturesPfizer Venture InvestmentsSR One Capital ManagementBioHealth Innovation, Inc.Takeda Ventures
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in
Co-investorsCatalio Capital Management, LPRA CapitalSamsara BioCapitalThird Rock Ventures
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)
Co-investors8VCARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)JDRF T1D FundLAV+6 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerARCH Venture PartnersFoothill VenturesIllumina VenturesMedical Excellence Capital+8 more
TORL BioTherapeutics develops antibody-drug conjugates (ADCs) targeting Claudin 6 (CLDN6) for the treatment of solid tumors such as ovarian, lung, endometrial, and testicular cancers.
BiotechHealthtechCulver City, US
Dave LicatainAran Maree M.D.inMark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)
Co-investorsOCV PartnersRA CapitalCowen Healthcare InvestmentsGoldman SachsPerceptive Xontogeny Venture
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
BlackThorn TherapeuticsCardero Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.